



(12) Translation of
European patent specification

(11) NO/EP 2342223 B1

NORWAY

(19) NO
(51) Int Cl.
C07K 14/505 (2006.01)
A61P 7/06 (2006.01)
C12N 5/10 (2006.01)
C12N 15/11 (2006.01)
C12N 15/16 (2006.01)
C12P 21/02 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2017.09.11
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.04.26
(86)	European Application Nr.	09816953.5
(86)	European Filing Date	2009.09.25
(87)	The European Application's Publication Date	2011.07.13
(30)	Priority	2008.09.26, US, 100679 P 2008.09.26, US, 100692 P
(84)	Designated Contracting States:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
	Designated Extension States:	AL BA RS
(73)	Proprietor	Ambrx, Inc., 10975 North Torrey Pines Road, Suite 100, La Jolla, CA 92037, US-USA ELI LILLY AND COMPANY, Lilly Corporate Center, Indianapolis, IN 46285, US-USA
(72)	Inventor	TIAN, Feng, 9003 Buckwheat Street, San Diego, CA 92129, US-USA HAYS PUTNAM, Anna-Maria, A., 11522 Cesped Drive, San Diego, CA 92124, US-USA SONG, Frank, 12016 Caminito Campana, San Diego, CA 92128, US-USA CHU, Stephanie, 4220 Porte De Palmas 34, San Diego, CA 92122, US-USA SHEFFER, Joseph, 2549 Montgomery Avenue, Cardiff, CA 92007, US-USA BARNETT, Richard, S., 306 Belmont Court, San Marcos, CA 92069, US-USA SILADI, Marc, 4077 Illinois Street 1, San Diego, CA 92104, US-USA ATKINSON, Kyle, 12580 Caminito Mira Del Mar, San Diego, CA 92130, US-USA LEE, Darin, 3187 Cowley Way Unit 263, San Diego, CA 92117, US-USA CANNING, Peter, C., 6652 Braemar Avenue, Noblesville, IN 46062, US-USA
(74)	Agent or Attorney	Zacco Norway AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54) Title **MODIFIED ANIMAL ERYTHROPOIETIN POLYPEPTIDES AND THEIR USES**

(56) References
Cited: EP-A1- 1 929 860
 WO-A2-94/24160
 WO-A2-2008/065372
 US-A1- 2008 097 083

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Katteerytropoietin(fEPO)-polypeptid omfattende en ikke-naturlig kodet aminosyre koblet til en vannoppløselig polymer, hvori:

5 aminosyren tilsvarende posisjon 1 i SEQ ID No 2 er substituert med den ikke-naturlig kodede aminosyren;
den ikke-naturlig kodede aminosyren er para-acetylphenylalanin; og
den vannoppløselige polymeren omfatter en oksyaminopoly(etylenglykol)-enhet med en molekylvekt på 20 kD, 30 kD eller 40 kD.

10

2. Katteerytropoietin(fEPO)-polypeptid ifølge krav 1, hvori den vannoppløselige polymeren omfatter en oksyaminopoly(etylenglykol)-enhet med en molekylvekt på 30 kD.

15

3. Sammensetning omfattende fEPO-polypeptidet ifølge krav 1 eller krav 2 og et farmasøytisk akseptabelt bærestoff.

4. fEPO-polypeptid ifølge krav 1 eller krav 2 for anvendelse som medikament.

20

5. fEPO-polypeptid ifølge krav 1 eller krav 2 for anvendelse i behandlingen av anemi.